Results 51 to 60 of about 4,362 (171)

Shifting From Systemic to Precision‐Targeted Complement Therapies: Opportunities and Hurdles

European Journal of Immunology, Volume 56, Issue 6, June 2026.
Complement therapeutics have expanded considerably, but systemic inhibitors remain limited by infection risks, breakthrough events, and loss of physiological functions. Emerging targeted approaches aim for organ‐, tissue‐, or cell‐specific modulation of complement activity, potentially offering greater precision while reducing treatment burden and ...
Marco Mannes, Wioleta M. Zelek, Leendert A. Trouw   +2 more
wiley   +1 more source

C3 glomerulopathies: dense deposit disease and C3 glomerulonephritis

Frontiers in Medicine, 2023
Dense deposit disease (DDD) and C3 glomerulonephritis (C3GN) are types of membranoproliferative glomerulonephritis classified as C3 glomerulopathies. These conditions are characterized by an increased number of intraglomerular cells and diffuse thickening of the glomerular capillary walls, along with the deposition of C3 and minimal or absent ...
Claudio Ponticelli, Marta Calatroni, Marta Calatroni, Gabriella Moroni, Gabriella Moroni   +4 more
openaire   +3 more sources

Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteers

British Journal of Pharmacology, Volume 183, Issue 11, Page 2874-2889, June 2026.
Abstract Background and Purpose Overactivation of the alternative pathway (AP) underlies several diseases. Iptacopan is an oral, first‐in‐class, highly potent specific inhibitor of factor B, a key AP protease. Experimental Approach The analysis included data from two phase 1 randomised, volunteer‐blinded, placebo‐controlled studies: Study 1, a single ...
Irina Baltcheva, Guido Junge, Kenneth Kulmatycki, Robert Schmouder, Anna Schubart, Marie‐Anne Valentin   +5 more
wiley   +1 more source

C3 Glomerulopathy: A Rare Entity with Future Directions

Revista Portuguesa de Nefrologia e Hipertensão, 2023
C3 glomerulopathies are a rare group of glomerular diseases resulting from excessive activation of the alternative complement pathway. The pathogenesis involves genetic, acquired, or immunologic defects in regulators of the alternative complement ...
Sara Vilela, Catarina Cardoso, Sara Barreto, Gonçalo Cruz, Pedro Bravo, Cristina Santos   +5 more
doaj   +1 more source

Glomerular Capillary Microaneurysms in Membranoproliferative Glomerulonephritis: A Clinicopathological Study Highlighting the Involvement of IgG3

Pathology International, Volume 76, Issue 6, June 2026.
Glomerular capillary microaneurysms (GCMs) were most frequently observed in proliferative glomerulonephritis with monoclonal immunoglobulin G deposits (PGNMID) among MPGN‐pattern glomerular diseases, but were not restricted to this entity. These lesions were characterized by exclusive IgG3‐dominant glomerular deposition, irrespective of light‐chain ...
Akiko Mii, Tomohiro Kaneko, Momoko Arai, Takehisa Yamada, Mayuko Takeuchi, Tetsuya Kashiwagi, Naomi Kuwahara, Arimi Ishikawa, Ryuji Ohashi, Yukinao Sakai, Masato Iwabu, Akira Shimizu   +11 more
wiley   +1 more source

PLA2R‐Positive Membranous Nephropathy and AA Amyloidosis in an Ethiopian Patient With Chronic Hepatitis B: A Case Report

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT The coexistence of primary phospholipase A2 receptor positive membranous nephropathy and AA amyloidosis in a patient with chronic hepatitis B is an exceedingly rare triad presenting a profound diagnostic and therapeutic challenge. A 38‐year‐old Ethiopian man with nephrotic syndrome and chronic hepatitis B had dual pathology on renal biopsy ...
Betelhem Abreham, Leja Hamza, Azeb Kebede, Daniel Rebuma Bekele, Zekarias Amdemariam   +4 more
wiley   +1 more source

C3 Glomerulonephritis: A Rare Etiology of the Pulmonary Renal Syndrome

Kidney Medicine, 2019
C3 Glomerulopathy is a rare form of kidney disease due to dysregulation of the alternative complement pathway. We report a case of a college-aged woman with C3 glomerulonephritis (C3GN), presenting with the unexpected extrarenal manifestation of ...
Shane A. Bobart, Sanjeev Sethi, Fernando C. Fervenza   +2 more
doaj   +1 more source

Current concepts in C3 glomerulopathy

Indian Journal of Nephrology, 2014
Complement component 3 glomerulopathy (C3G) is a recently defined entity comprising of dense deposit disease and C3 glomerulonephritis. The key histological feature is the presence of isolated C3 deposits without immunoglobulins. Often masqueradng as some of the common glomerulonephritides this is a prototype disorder occurring from dysregulated ...
Thomas, S., Ranganathan, D., Francis, L., Madhan, K., John, G. T.   +4 more
openaire   +2 more sources

C3 Glomerulopathy: Novel Treatment Paradigms

Kidney International Reports
C3 glomerulopathy (C3G) is diagnosed by kidney biopsy, with immunofluorescence showing isolated or dominant C3 staining, indicating hyperactivity of the alternative complement pathway as the key driver of glomerular injury.
Blanca Tarragon Estebanez, Andrew S. Bomback   +1 more
doaj   +1 more source

Multimodal imaging of retinal pigment epithelial detachments in patients with C3 glomerulopathy: case report and review of the literature

BMC Ophthalmology, 2017
Background To describe the optical coherence tomography angiograhy (OCTA) of drusenoid pigment epithelial detachments (PEDs) in a woman affected by Complement 3 (C3) glomerulopathy, which represents a spectrum of glomerular diseases characterized on ...
Valeria Kheir, Ali Dirani, Matthieu Halfon, Jean-Pierre Venetz, Georges Halabi, Yan Guex-Crosier   +5 more
doaj   +1 more source